Hutchmed And Takeda Announced That Results Of Phase 3 FRESCO-2 Study Of Fruquintinib In Patients With Previously Treated Metastatic Colorectal Cancer Were Published In The Lancet, Showing That Fruquintinib Reduced The Risk Of Death By 34%
Portfolio Pulse from Benzinga Newsdesk
Hutchmed and Takeda announced positive results from their Phase 3 FRESCO-2 study of Fruquintinib in patients with previously treated metastatic colorectal cancer, published in The Lancet. The study showed a 34% reduction in the risk of death.
June 16, 2023 | 8:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hutchmed's Fruquintinib Phase 3 study with Takeda shows a 34% reduction in risk of death for metastatic colorectal cancer patients.
The positive results from the Phase 3 FRESCO-2 study of Fruquintinib indicate a potential increase in demand for the drug, which could lead to increased revenues for Hutchmed. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50
POSITIVE IMPACT
Takeda's partnership with Hutchmed in the Phase 3 FRESCO-2 study of Fruquintinib shows a 34% reduction in risk of death for metastatic colorectal cancer patients.
The positive results from the Phase 3 FRESCO-2 study of Fruquintinib indicate a potential increase in demand for the drug, which could lead to increased revenues for Takeda. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50